News | Blood Testing | September 04, 2018

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

Prevencio’s multi-protein, AI-driven HART PAD biomarker test has potential to improve clinical outcomes and reduce costs in the treatment of diabetic patients

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient

September 4, 2018 — Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June demonstrating Prevencio’s HART CAD and HART CVE tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in DM patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.

In this study, researchers assessed the company’s artificial intelligence (AI)-driven HART PAD diagnostic test on patients enrolled in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study. The HART PAD test algorithmically assesses six biomarkers linked to atherosclerosis, as well as a patient’s history of hypertension. In patients with DM, the HART PAD panel had excellent performance for diagnosis of PAD. Using a five-point score, a score of 1 had a 100 percent negative predictive value (NPV) and a score of 5 had a 95 percent positive predictive value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularization in patients with PAD. These results were comparable to those patients without DM.

Principal investigator James L. Januzzi, M.D., practicing cardiologist at MGH and professor of medicine at Harvard Medical School, said, “The HART PAD test may allow for the diagnosis and treatment of many more patients with currently undetected PAD. In the clinical setting, these findings could assist physicians to identify peripheral artery disease earlier, provide guideline-recommended care and monitor at-risk patients for vascular complications. We believe HART tests could also play an important role in identifying high-risk patients for enrollment in clinical trials, thereby saving time and lowering overall trial costs.”

PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with DM are at substantial risk of developing PAD. Patients with PAD have increased risk of CAD, heart attack or stroke and, if left untreated, PAD can lead to foot or leg amputation.

For more information: www.prevenciomed.com

Related Content

Artificial Intelligence in medical imaging was the top trend and buzz at RSNA 2018.

Artificial intelligence in medical imaging was the major buzz at RSNA 2018. The expo floor had a dedicated area just to highlight artificial intelligence software for medical imaging. More than 150 vendors on the expo floor were showing software using some level of AI or deep learning. 

Feature | Artificial Intelligence | January 17, 2019 | Dave Fornell, Editor
Artificial intelligence (AI) was by far the hottest trend discussed in sessions and across the expo floor at the worl
Artificial Intelligence Advances Threaten Privacy of Health Data
News | Artificial Intelligence | January 04, 2019
Advances in artificial intelligence (AI) have created new threats to the privacy of people's health data, a new...
Videos | Artificial Intelligence | December 12, 2018
This is a quick video tour of the Machine Learning Showcase at the ...
Bay Labs Collaborating With Edwards Lifesciences on AI for Heart Disease Detection
News | Artificial Intelligence | December 10, 2018
Medical artificial intelligence (AI) company Bay Labs announced a collaboration with Edwards Lifesciences focused on...
An example of artificial intelligence-aided clinical decision support software for a heart failure patient from the vendor HealthReveal. The AI pulled in relevant patient data from the electronic medical record and offers recommendations for care based on current American Heart Association (AHA) guidelines. It also offers the citations for where to find the guidelines and prescribing information for the recommended drug. Machine learning for cardiology.

An example of artificial intelligence-aided clinical decision support software for a heart failure patient from the vendor HealthReveal. The AI pulled in relevant patient data from the electronic medical record and offers recommendations for care based on current American Heart Association (AHA) guidelines. It also offers the citations for where to find the guidelines and prescribing information for the recommended drug.

Feature | Artificial Intelligence | December 06, 2018 | Lonny Reisman, M.D.
The consistent provision of guideline-directed medical therapy (GDMT) — care delivered according to established guide
AI Predicts Cardiovascular Disease Risk From CT Scans
News | Artificial Intelligence | November 27, 2018
November 27, 2018 – Zebra Medical Vision and Clalit Health Services announced the completion of a research project th
AI Algorithm Outperforms Most Cardiologists in Heart Murmur Detection
News | Artificial Intelligence | November 11, 2018
At the American Heart Association’s (AHA) Scientific Sessions 2018, Nov. 10-12 in Chicago, Eko presented a clinical...
Overlay Init